Naxat (Rivaroxaban)

Rivaroxaban is indicated for several thromboembolic conditions and works by targeting the coagulation cascade.

• Non‑valvular atrial fibrillation: reduces risk of stroke and systemic embolism.
• Deep vein thrombosis (DVT): treats acute events and prevents recurrence.
• Pulmonary embolism (PE): treats acute episodes and reduces recurrence.
• Orthopedic surgery prophylaxis: prevents DVT after hip or knee replacement.

• Rivaroxaban selectively and directly inhibits factor Xa, a key enzyme in the coagulation cascade that converts prothrombin to thrombin. By blocking factor Xa activity, it reduces thrombin generation, limits fibrin clot formation, and thereby diminishes the likelihood of pathological thrombosis without requiring antithrombin as a cofactor.

Rivaroxaban may cause a range of adverse reactions, from mild to serious.

Common Side Effects

• Bruising or minor bleeding: easy bruising or small cuts that bleed longer than usual.
• Nosebleeds: occasional epistaxis without trauma.
• Gastrointestinal upset: nausea, dyspepsia, or abdominal discomfort.
• Headache: mild to moderate intensity.
• Dizziness: transient light‑headedness.

Serious or Rare Side Effects

• Major bleeding: gastrointestinal, intracranial, or fatal hemorrhage.
• Spinal or epidural hematoma: risk after neuraxial procedures.
• Hepatic injury: elevated liver enzymes or hepatitis.
• Allergic reactions: rash, pruritus, or anaphylaxis.
• Thrombocytopenia: low platelet counts leading to bleeding.

Before prescribing rivaroxaban, clinicians should evaluate patient‑specific risk factors and monitor therapy closely.

• Renal function assessment: adjust dosing in impaired clearance.
• Bleeding risk evaluation: review history of hemorrhage or bleeding disorders.
• Concomitant antiplatelet use: consider increased bleeding potential.
• Hepatic impairment: avoid in severe liver disease.
• Active major bleeding: discontinue immediately.
• Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Rivaroxaban interacts with several drug classes that can alter its anticoagulant effect.

Major Interactions (Avoid)

• Other anticoagulants (e.g., warfarin, heparin): additive bleeding risk.
• Strong CYP3A4 and P‑gp inhibitors (e.g., ketoconazole, ritonavir): increase plasma levels.
• Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): reduce efficacy.

Moderate Interactions (Monitor Closely)

• Antiplatelet agents (e.g., aspirin, clopidogrel): heightened bleeding.
• NSAIDs (e.g., ibuprofen, naproxen): gastrointestinal bleeding risk.
• SSRIs or SNRIs (e.g., fluoxetine, venlafaxine): may increase bleeding tendency.